A non-randomized, single-center phase II study of bevacizumab in combination with etoposide plus cisplatin in patients with extended-stage small cell lung cancer (SCLC), who have not received prior chemotherapy.

Trial Profile

A non-randomized, single-center phase II study of bevacizumab in combination with etoposide plus cisplatin in patients with extended-stage small cell lung cancer (SCLC), who have not received prior chemotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2010

At a glance

  • Drugs Bevacizumab; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 11 Jun 2010 Status changed from not yet recruiting to discontinued as reported by Roche record.
    • 22 Apr 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top